DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for leprosy — screening already-approved drugs against its 26-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLeprosy maps to a 26-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for leprosy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tenascin C (TNC) — TNC is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-methyl-1,2,4-thiadiazol-5-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5R61 · 1.38 Å · ligand 1-(3-methyl-1,2,4-thiadiazol-5-yl)-1,4-diazepane (K1P). Experimental structure, not a prediction.
What the evidence adds up to
A 2017 review of leprosy treatment summarises the evolution from dapsone monotherapy to the World Health Organization’s recommended multidrug therapy, and notes a recent proposal for a single fixed six-month regimen for all clinical presentations, regardless of classification. The review does not provide survival or response rate data. A 1974 review states that advances in chemotherapy were beginning to place treatment on an objective bacteriological and pharmacological basis, but gives no concrete numbers.
A 2013 review of pathogenesis describes newly identified markers associated with localised or disseminated disease and leprosy reactions, including human interferons, CD163, microRNA-21, NOD2, galectin-3 and toll-like receptor 4. It also mentions a newly identified species, Mycobacterium lepromatosis, detected in patients with leprosy and severe erythema nodosum leprosum. The review calls for larger numbers of clinical samples across the leprosy spectrum.
A 2021 study in Ceará, Brazil, diagnosed 1,777 leprosy relapse cases between 2001 and 2018. Higher relapse prevalence was found in men, illiterates, mixed-race individuals, multibacillary leprosy, lepromatous leprosy, and persons with visible disabilities. The proportion of relapse increased over the study period. No relapse rates or survival figures are given.
What is still missing is a standardised, large-scale trial comparing the proposed uniform six-month regimen against current multidrug therapy with relapse as a primary endpoint, and prospective studies that stratify patients by the newly identified immunological and genetic markers to predict relapse or reaction risk. Funding for such trials and for long-term follow-up in endemic regions remains insufficient.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Anais Brasileiros de Dermatologia · 2017 · 104 citations · open access
Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients
AbstractIn this review, the most relevant and current epidemiological data, the main clinical, laboratory and therapeutical aspects of leprosy are presented. Detailed discussion of the main drugs used for leprosy treatment, their most relevant adverse effects, evolution of the therapeutic regimen, from dapsone as a monotherapy to the proposed polychemotherapy by World Health Organization (WHO) can be found in this CME. We specifically highlight the drug acceptability, reduction in treatment duration and the most recent proposal of a single therapeutic regimen, with a fixed six months duration, for all clinical presentations, regardless of their classification.
Current Opinion in Infectious Diseases · 2013 · 59 citations
New findings in the pathogenesis of leprosy and implications for the management of leprosy
AbstractPURPOSE OF REVIEW: This review focuses on recent work in leprosy pathogenesis. New research of both innate and adaptive immune responses to Mycobacterium leprae is described. The proposition that Mycobacterium lepromatosis is a new species causing leprosy is discussed. RECENT FINDINGS: Modulation of the lipid metabolism and reprogramming of adult Schwann cells have both been suggested as mechanisms used by M. leprae to disseminate the disease. New markers associated with localized, disseminated disease or the occurrences of leprosy reactions include the human interferons, CD163, microRNA-21, NOD2, galectin-3 and toll-like receptor 4. The role of keratinocytes instead of macrophages is underlined in the pathogenesis of leprosy. Adaptive immunity reports focus on the role of T regulatory cells and cytokines secreted by T helper cells in leprosy. Finally, a newly identified species named M. lepromatosis has been detected in patients with leprosy and severe erythema nodosum leprosum. SUMMARY: Novel biological pathways have been identified to be associated with the clinical phenotype of leprosy or the occurrence of leprosy reactions. Future work should include larger numbers of clinical samples from across the leprosy spectrum in order to give new insights in the pathogenesis and management of the disease.
AbstractRecent advances in the chemotherapy of human and experimental leprosy are reviewed. These advances are begining to place the treatment of leprosy on an objective bacteriological and pharmacological basis. The relevance of these recent studies to designing more effective and more conveniently administered regimens for the successful treatment of lepromatous leprosy is discussed .
Revista da Sociedade Brasileira de Medicina Tropical · 2021 · 7 citations · open access
Magnitude and temporal trends of leprosy relapse in the state of Ceará, Brazil in the period 2001-2018
AbstractINTRODUCTION: This study analyzed the magnitude and temporal trends of leprosy relapse in Ceará in 2001-2018. METHODS: Descriptive cross-sectional and ecological-time trend studies were performed. RESULTS: We diagnosed 1,777 leprosy relapse cases. Higher prevalence of relapse was observed in men, illiterates, mixed race, multibacillary leprosy, lepromatous leprosy, and persons with visible disabilities. The proportion of relapse increased throughout the study period. CONCLUSIONS: Leprosy relapse is prevalent in certain groups.
Transactions of the Royal Society of Tropical Medicine and Hygiene · 1953 · 3 citations
The treatment of leprosy with isonicotinyl hydrazine a case report
AbstractJournal Article The treatment of leprosy with isonicotinyl hydrazine. A case report Get access Wm. Holmes Taylor Wm. Holmes Taylor Heri Mission Hospital of Seventh-day Adventists, Manyovu, Kasulu, Tanganyika Kenya Search for other works by this author on: Oxford Academic PubMed Google Scholar Transactions of The Royal Society of Tropical Medicine and Hygiene, Volume 47, Issue 4, July 1953, Pages 334–335, https://doi.org/10.1016/0035-9203(53)90058-3 Published: 01 July 1953
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
